431 related articles for article (PubMed ID: 26712873)
21. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
[TBL] [Abstract][Full Text] [Related]
22. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.
Murthy SS; Sandhya DG; Ahmed F; Goud KI; Dayal M; Suseela K; Rajappa SJ
Indian J Pathol Microbiol; 2011; 54(3):532-8. PubMed ID: 21934215
[TBL] [Abstract][Full Text] [Related]
23. Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results.
Wang B; Ding W; Sun K; Wang X; Xu L; Teng X
Sci Rep; 2019 Nov; 9(1):16726. PubMed ID: 31723206
[TBL] [Abstract][Full Text] [Related]
24. Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study.
Hanna WM; Barnes PJ; Chang MC; Gilks CB; Magliocco AM; Rees H; Quenneville L; Robertson SJ; SenGupta SK; Nofech-Mozes S
J Clin Oncol; 2014 Dec; 32(35):3967-73. PubMed ID: 25385731
[TBL] [Abstract][Full Text] [Related]
25. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
[TBL] [Abstract][Full Text] [Related]
26. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
27. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies.
Lebeau A; Turzynski A; Braun S; Behrhof W; Fleige B; Schmitt WD; Grob TJ; Burkhardt L; Hölzel D; Jackisch C; Thomssen C; Müller V; Untch M
J Clin Oncol; 2010 Jul; 28(20):3264-70. PubMed ID: 20498397
[TBL] [Abstract][Full Text] [Related]
28. Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramatically increases health care costs.
VandenBussche CJ; Cimino-Mathews A; Park BH; Emens LA; Tsangaris TN; Argani P
Am J Surg Pathol; 2015 Jul; 39(7):939-47. PubMed ID: 25871620
[TBL] [Abstract][Full Text] [Related]
29. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer.
Asogan AB; Hong GS; Arni Prabhakaran SK
Singapore Med J; 2017 Mar; 58(3):145-149. PubMed ID: 27029805
[TBL] [Abstract][Full Text] [Related]
30. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.
Schalper KA; Kumar S; Hui P; Rimm DL; Gershkovich P
Arch Pathol Lab Med; 2014 Feb; 138(2):213-9. PubMed ID: 24164555
[TBL] [Abstract][Full Text] [Related]
31. Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update.
Gordian-Arroyo AM; Zynger DL; Tozbikian GH
Am J Clin Pathol; 2019 Jun; 152(1):17-26. PubMed ID: 30958889
[TBL] [Abstract][Full Text] [Related]
32. The impact of 2018 ASCO-CAP HER2 testing guidelines on breast cancer HER2 results. An audit of 2132 consecutive cases evaluated by immunohistochemistry and in situ hybridization.
Farshid G; Dhatrak D; Gilhotra A; Koszyca B; Nolan J
Mod Pathol; 2020 Sep; 33(9):1783-1790. PubMed ID: 32366941
[TBL] [Abstract][Full Text] [Related]
33. Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast.
Lee AH; Key HP; Bell JA; Hodi Z; Ellis IO
Histopathology; 2012 May; 60(6):880-4. PubMed ID: 22320892
[TBL] [Abstract][Full Text] [Related]
34. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Wolff AC; Hammond ME; Hicks DG; Dowsett M; McShane LM; Allison KH; Allred DC; Bartlett JM; Bilous M; Fitzgibbons P; Hanna W; Jenkins RB; Mangu PB; Paik S; Perez EA; Press MF; Spears PA; Vance GH; Viale G; Hayes DF; ;
Arch Pathol Lab Med; 2014 Feb; 138(2):241-56. PubMed ID: 24099077
[TBL] [Abstract][Full Text] [Related]
35. [Availability of fine needle aspirates for the assessment of HER2 gene amplification in invasive breast cancer patients].
Lee JW; Noh WC; Kim MS; Kim HA; Chang YH; Hong YJ; Hong SI; Lee JK
Korean J Lab Med; 2008 Oct; 28(5):392-9. PubMed ID: 18971621
[TBL] [Abstract][Full Text] [Related]
36. HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor.
Liu Y; Wu S; Shi X; Luo Y; Pang J; Wang C; Mao F; Liang Z; Zeng X
Breast Cancer Res Treat; 2019 Nov; 178(2):275-281. PubMed ID: 31388934
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
[TBL] [Abstract][Full Text] [Related]
38. Impact of 2013 ASCO/CAP guidelines on HER2 determination of invasive breast cancer: A single institution experience using frontline dual-color FISH.
Ragazzi M; Bisagni A; Gasparini E; Kuhn E; Bassano C; Tamagnini I; Foroni M; Bortesi M; Falco G; Ferrari G; Braglia L; Savoldi L; Bologna A; Di Cicilia R; Bisagni G; Gardini G
Breast; 2017 Aug; 34():65-72. PubMed ID: 28521178
[TBL] [Abstract][Full Text] [Related]
39. Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization.
Solomon JP; Dell'Aquila M; Fadare O; Hasteh F
Am J Clin Pathol; 2017 Apr; 147(4):432-437. PubMed ID: 28340220
[TBL] [Abstract][Full Text] [Related]
40. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
Middleton LP; Price KM; Puig P; Heydon LJ; Tarco E; Sneige N; Barr K; Deavers MT
Arch Pathol Lab Med; 2009 May; 133(5):775-80. PubMed ID: 19415952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
